Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTKILTI) Complex Protein (Monomer, MALS verified)

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV) . The hepatitis B virus attacks the liver and can cause both acute and chronic diseases that put people at high risk of death from cirrhosis and liver cancer. The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids. Hepatitis B virus (HBV) is a member of the hepadnaviral family. The virus particle (virion) consists of an outer lipid envelope and an icosahedral nucleocapsid core composed of the core protein. The nucleocapsid encloses the viral DNA and a DNA polymerase that has reverse transcriptase activity. The outer envelope contains embedded proteins that are involved in viral binding of, and entry into, susceptible cells. The surface antigens (HBsAg) decorating the lipid envelope of HBV are produced in excess during the life cycle of the virus, and its presence in blood indicates current hepatitis B infection. The Human HLA-A*0201 HBV (FLLTKILTI) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and FLLTKILTI peptide of the HBV.

Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTKILTI) Complex Protein is produced by co-expression of HLA and B2M loaded with HBV peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-42 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Immobilized Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTKILTI) Complex Protein (Cat. No. HLT-H82E7) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (QC tested).